22:13 , Feb 22, 2019 |  BC Extra  |  Politics & Policy

China releases list of rare disease drugs with reduced VAT

China’s ministry of finance revealed a list of 21 rare disease drugs and four APIs which will be eligible for a reduction in value-added tax beginning March 1. The government will reduce the VAT on...
00:38 , Feb 8, 2019 |  BC Innovations  |  Product R&D

Reducing R(i)SK in TNBC

Phoenix Molecular Designs could provide triple-negative breast cancer its first molecular marker to turn the intractable indication from a group of have-nots to a group of haves. With early evidence that RSK2 is activated in...
23:18 , Feb 1, 2019 |  BioCentury  |  Product Development

Year of the lion

With three data readouts coming in 2019, Aslan Pharmaceuticals Ltd. is hoping this will be the year it starts to reap the benefits of its 2012 strategy rethink, giving the biotech more options for advancing...
01:08 , Feb 1, 2019 |  BC Week In Review  |  Company News

AZ, UPMC in value-based agreement for Brilinta

To reduce out-of-pocket costs for Medicare patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor that links reimbursement of the drug to cardiovascular outcomes following a recent hospitalization...
22:22 , Jan 28, 2019 |  BC Extra  |  Company News

AZ, UPMC in value-based agreement for Brilinta

To reduce out-of-pocket costs for Medicare patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor that links reimbursement of the drug to cardiovascular outcomes following a recent hospitalization...
20:41 , Jan 18, 2019 |  BC Week In Review  |  Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
00:59 , Jan 18, 2019 |  BC Week In Review  |  Company News

Bioharmony, Boehringer partner to develop antimicrobials

Antimicrobial company Bioharmony Therapeutics Inc. (New York, N.Y.) partnered with Boehringer Ingelheim GmbH (Ingelheim, Germany) to develop bacteriophage lysins to treat systemic multidrug-resistant Acinetobacter infections. Bioharmony declined to disclose financial terms and details regarding the...
23:21 , Jan 17, 2019 |  BC Extra  |  Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
21:58 , Jan 15, 2019 |  BC Extra  |  Company News

Bioharmony, Boehringer partner to develop antimicrobials

Antimicrobial company Bioharmony Therapeutics Inc. (New York, N.Y.) partnered with Boehringer Ingelheim GmbH (Ingelheim, Germany) to develop bacteriophage lysins to treat systemic multidrug-resistant Acinetobacter infections. Bioharmony declined to disclose financial terms and details regarding the...
17:34 , Jan 9, 2019 |  BC Innovations  |  Distillery Therapeutics

Endocrine/metabolic

INDICATION: Metabolic Mouse studies suggest inhibiting SGLT2 could help treat G6PC3 deficiency-induced neutropenia. In a mouse model of G6PC3 deficiency, the SGLT2 inhibitor Jardiance empagliflozin decreased granulocyte maturation arrest in the bone marrow and increased...